Nuzenio

Kodiak Sciences

Kodiak Sciences news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 8 latest news signals 8 publisher sources 100/100 entity strength

Latest news

Kodiak Sciences (KOD) Is Up 9.1% After Advancing KSI-101 Phase 3 PEAK Trial Enrollment – Has The Bull Case Changed? - simplywall.stsimplywall.st · Sun, 09 Aug 2026 08:50:34 GMT LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $65 - MoomooMoomoo · Thu, 06 Aug 2026 21:31:00 GMT Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026 - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 11:00:00 GMT Kodiak Sciences Inc (KOD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKeyTradingKey · Wed, 05 Aug 2026 07:00:00 GMT KOD Maintained by JP Morgan -- Price Target Raised to $66.00 - GuruFocusGuruFocus · Mon, 03 Aug 2026 16:56:03 GMT KODIAK SCIENCES INC : JP MORGAN RAISES TARGET PRICE TO $66 FROM $56 - BitgetBitget · Mon, 03 Aug 2026 07:00:00 GMT Kodiak Sciences Inc Revenue Breakdown – NASDAQ:KOD - TradingViewTradingView · Sat, 01 Aug 2026 03:22:43 GMT KOD News | KODIAK SCIENCES INC (NASDAQ:KOD) - ChartMillChartMill · Fri, 31 Jul 2026 00:00:03 GMT

Timeline

Sun, 09 Aug 2026 08:50:34 GMTKodiak Sciences (KOD) Is Up 9.1% After Advancing KSI-101 Phase 3 PEAK Trial Enrollment – Has The Bull Case Changed? - simplywall.st

Thu, 06 Aug 2026 21:31:00 GMTLifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $65 - Moomoo

Thu, 06 Aug 2026 11:00:00 GMTKodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026 - Yahoo Finance

Wed, 05 Aug 2026 07:00:00 GMTKodiak Sciences Inc (KOD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Mon, 03 Aug 2026 16:56:03 GMTKOD Maintained by JP Morgan -- Price Target Raised to $66.00 - GuruFocus

Mon, 03 Aug 2026 07:00:00 GMTKODIAK SCIENCES INC : JP MORGAN RAISES TARGET PRICE TO $66 FROM $56 - Bitget

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

KOD9 live mentions Phase4 live mentions NASDAQ4 live mentions KODIAK SCIENCES INC3 live mentions Is Up2 live mentions After Advancing KSI2 live mentions PEAK Trial Enrollment2 live mentions Has The Bull2 live mentions Case Changed2 live mentions With Buy Rating2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Kodiak Sciences.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

8 distinct publisher/source names are currently connected to this entity page.